We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

95 hedge funds and large institutions have $227M invested in Aclaris Therapeutics in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

3.67% less ownership

Funds ownership: 95.46% → 91.79% (-3.7%)

4% less funds holding

Funds holding: 99 → 95 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

21% less capital invested

Capital invested by funds: $289M → $227M (-$61.5M)

76% less call options, than puts

Call options by funds: $68K | Put options by funds: $288K

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
95
Holders Change
-4
Holders Change %
-4.04%
% of All Funds
2.06%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
15
Increased
36
Reduced
25
Closed
19
Calls
$68K
Puts
$288K
Net Calls
-$220K
Net Calls Change
-$336K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$7.4M
2
ECM
Endurant Capital Management
California
+$3.62M
3
Man Group
Man Group
United Kingdom
+$3.44M
4
RSCM
Rock Springs Capital Management
Maryland
+$2.46M
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.2M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.6M
2
FCMI
Foresite Capital Management IV
California
-$5.53M
3
EC
EcoR1 Capital
California
-$4.54M
4
UBS Group
UBS Group
Switzerland
-$4.2M
5
BlackRock
BlackRock
New York
-$3.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
OAM
51
Oxford Asset Management
United Kingdom
$211K +$80K +12,072 +52%
CS
52
Credit Suisse
Switzerland
$200K +$888 +134 +0.4%
DekaBank Deutsche Girozentrale
53
DekaBank Deutsche Girozentrale
Germany
$187K +$13.9K +2,100 +20%
Invesco
54
Invesco
Georgia
$187K +$207K +31,234 New
Wells Fargo
55
Wells Fargo
California
$184K +$22.1K +3,329 +12%
New York State Common Retirement Fund
56
New York State Common Retirement Fund
New York
$178K – – –
Prudential Financial
57
Prudential Financial
New Jersey
$164K +$3.69K +557 +2%
OAC
58
OMERS Administration Corp
Ontario, Canada
$158K +$168K +25,400 New
Manulife (Manufacturers Life Insurance)
59
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$153K +$81.5K +12,288 +92%
AIG
60
American International Group
New York
$135K -$4.85K -731 -3%
CSS
61
Cubist Systematic Strategies
Connecticut
$127K -$430K -64,914 -75%
JG
62
Jefferies Group
New York
$127K -$63.6K -9,602 -31%
PP
63
Paloma Partners
Connecticut
$125K +$139K +20,900 New
Millennium Management
64
Millennium Management
New York
$125K +$139K +20,902 New
ProShare Advisors
65
ProShare Advisors
Maryland
$106K +$981 +148 +0.8%
Marshall Wace
66
Marshall Wace
United Kingdom
$103K +$114K +17,245 New
Susquehanna International Group
67
Susquehanna International Group
Pennsylvania
$90K +$99.2K +14,970 New
VOYA Investment Management
68
VOYA Investment Management
Georgia
$85K – – –
Citigroup
69
Citigroup
New York
$79K +$61.4K +9,260 +232%
VF
70
Virtu Financial
New York
$70K +$77.9K +11,758 New
UBS AM
71
UBS AM
Illinois
$68.1K +$75.4K +11,368 New
RG
72
Redmile Group
California
$68K – – –
Parallax Volatility Advisers
73
Parallax Volatility Advisers
California
$66K +$21.9K +3,300 +42%
State Board of Administration of Florida Retirement System
74
State Board of Administration of Florida Retirement System
Florida
$65K – – –
T. Rowe Price Associates
75
T. Rowe Price Associates
Maryland
$63K +$69.2K +10,446 New
1 2
3
4 5

ACRS Hedge Fund Activity: Q1 2019 in Review

95 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2019, worth a combined $227M — down 21% from $289M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ACRS and 15 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 36 added.

The largest buyer was Vanguard Group, adding an estimated $7.4M. The largest seller was Fidelity Investments, cutting an estimated $6.6M.

  • 95 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2019, down from 99 in Q4 2018.
  • Funds reported $227M of Aclaris Therapeutics stock for Q1 2019, down 21% quarter-over-quarter.
  • 15 funds opened new Aclaris Therapeutics positions in Q1 2019 and 19 closed out, a net change of -4 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $7.4M added.
  • The largest Aclaris Therapeutics seller in Q1 2019 was Fidelity Investments, an estimated $6.6M sold.

Based on aggregated 13F filings for Q1 2019.